FemPulse announced today that it received FDA investigational device exemption (IDE) approval for its overactive bladder (OAB ...
FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II pivotal clinical trial in female patients suffering ...
EndoQuest Robotics announced today that it received FDA investigational device exemption (IDE) for a study of its surgical ...
RapidPulse, Inc. announced FDA approval of an investigational device exemption (IDE) for the company to study the RapidPulse c ...
From a company layoff to FDA nods, here are five key developments from spine and orthopedic medtech companies since Dec. 4.
EndoQuest will commence its PARADIGM clinical trial for endoluminal robotic colorectal surgery at five leading US hospitals ...
In a multicenter, prospective, nonrandomized study evaluating outcomes of fenestrated-branched endovascular aortic repair (FB ...
NeuroPace (NPCE) announced completion of enrollment and implant procedures in its feasibility investigational device exemption, or IDE, study ...
In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.
Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.
ShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic Migraine
ShiraTronics, a clinical-stage innovator in neuromodulation technology, today announced the initiation of its U.S. Food and Drug Administration (FDA)-approved Investigation Device Exemption (IDE) ...
Issued earlier in 2024, FDA’s final rule on laboratory developed tests (LDTs) ended the agency’s long-standing policy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback